{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:51:18Z","timestamp":1757544678953},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T00:00:00Z","timestamp":1345680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>In the treatment of acute schizophrenia, risperidone and aripiprazole are both placed the first line antipsychotics. These two antipsychotics have different pharmacological effects. We investigated the effects of risperidone on plasma levels of homovanillic acid (HVA) and 3\u2010methoxy\u20104hydroxyphenylglycol after unsuccessful aripiprazole treatment in acute schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ten Japanese patients with acute schizophrenia were enrolled to this study. Plasma levels of monoamine metabolites were analyzed with high\u2010performance liquid chromatography with electrochemical detection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Risperidone improved the symptoms and 4 of 10 patients were responders. Risperidone showed a tendency to decrease plasma HVA (pHVA) levels in responders (<jats:italic>p<\/jats:italic>\u2009=\u20090.068), but not in non\u2010responders (<jats:italic>p<\/jats:italic>\u2009=\u20091.0). At baseline, pHVA levels of responders were significantly higher than that of non\u2010responders (<jats:italic>p<\/jats:italic>\u2009=\u20090.033). A trend for negative correlation was found between pHVA at baseline and the changes in Positive and Negative Syndrome Scale\u2010Total (<jats:italic>p<\/jats:italic>\u2009=\u20090.061, <jats:italic>r<\/jats:italic>\u2009=\u2009\u22120.61).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results suggest that high pHVA level before switching may predict good response to the second line antipsychotics after unsuccessful first antipsychotic treatment. If aripiprazole is not effective in acute schizophrenia, switching to risperidone may be effective and reasonable strategy for improving symptoms. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2251","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T03:21:00Z","timestamp":1345778460000},"page":"517-520","source":"Crossref","is-referenced-by-count":3,"title":["Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia"],"prefix":"10.1002","volume":"27","author":[{"given":"Itaru","family":"Miura","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, School of Medicine Fukushima Medical University  Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, School of Medicine Fukushima Medical University  Fukushima Japan"},{"name":"Department of Neuropsychiatry Hoshigaoka Hospital  Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Katsumi","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, School of Medicine Fukushima Medical University  Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kanno","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, School of Medicine Fukushima Medical University  Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fukushima Medical University Hospital  Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirobumi","family":"Mashiko","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, School of Medicine Fukushima Medical University  Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin\u2010Ichi","family":"Niwa","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, School of Medicine Fukushima Medical University  Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,8,23]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"113","volume-title":"Psychopharmacology: The Third Generation of Progress","author":"Bunney BS","year":"1987"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.033175"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac00126a067"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200301000-00007"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0903"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000192138.53769.43"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00094-3"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6849119"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1980.tb11240.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31823f87ac"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.681"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.685"},{"issue":"7","key":"e_1_2_6_14_1","first-page":"1","article-title":"Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmap","volume":"68","author":"Weiden PJ","year":"2007","journal-title":"J Clin Psychiaty"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2251","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:20:06Z","timestamp":1695471606000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,23]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/hup.2251"],"URL":"https:\/\/doi.org\/10.1002\/hup.2251","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,23]]}}}